Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | SVP&Pres, LillyDiab & LillyUSA | February 04, 2019 | February 20, 2019 |
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | July 07, 2023 | July 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date February 04, 2019 · Filed February 20, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,962 |
Reported balance
After 2019-02-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2019-02-04 · Grant · Acquired 26,682 · Balance 157,962 F1: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5.
KYNTRA BIO, INC.
Report date July 07, 2023 · Filed July 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 374,722 |
Reported balance
After 2023-07-07 transaction · row 1
1 source rowRow 1 · 2023-07-07 · Sale · Disposed 1,880 · Balance 374,722 F1: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 27,800 |
Reported balance
Holding disclosure · report date 2023-07-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 27,800 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2023 Filed Jul 10, 2023 23:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,880 | $2.80 | $5,264.00 |
DisclosureSEC source: 0001209191-23-041969 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,722 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 23:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,106 | $17.04 | $104,033.42 |
DisclosureSEC source: 0001209191-23-036051 · doc4.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,602 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 23:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,791 | $17.04 | $47,549.71 |
DisclosureSEC source: 0001209191-23-036051 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,708 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F2 · balance_after: Includes 2,500 shares acquired on May 15, 2023 through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 20:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,869 | $19.52 | $36,482.88 |
DisclosureSEC source: 0001209191-23-024026 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,999 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| March 10, 2023 Filed Mar 11, 2023 02:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 19,486 | $20.20 | $393,564.59 |
DisclosureSEC source: 0001209191-23-018064 · doc4.xml · nonDerivative · entry 5 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,868 F4 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of PSU TSR previously reported in Table I. Read SEC document |
| March 10, 2023 Filed Mar 11, 2023 02:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 12,103 | $20.20 | $244,447.92 |
DisclosureSEC source: 0001209191-23-018064 · doc4.xml · nonDerivative · entry 4 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,357 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| March 10, 2023 Filed Mar 23, 2023 20:50 UTC Amendment | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 19,489 | $20.20 | $393,625.18 |
DisclosureSEC source: 0001209191-23-020781 · doc4a.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,868 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of PSU TSR previously reported in Table I. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 02:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 37,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018064 · doc4.xml · nonDerivative · entry 3 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,460 F3 · shares: Represents the number of shares released for PSU TSR Grant vested on March 8, 2023. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 02:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 23,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018064 · doc4.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,231 F2 · shares: Represents the number of shares released for PSU Milestone Grant vested on March 8, 2023. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 02:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 24,672 | $21.16 | $521,958.36 |
DisclosureSEC source: 0001209191-23-018064 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,111 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 01:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 143,100 | $0.00 Strike: $22.60 | $0.00 |
DisclosureSEC source: 0001209191-23-012423 · doc4.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,100 Underlying: Common Stock · 143,100 shares Expires 2033-02-20 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option will vest on March 1, 2024, and the remainder of the options will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 01:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 85,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012423 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,783 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent of the RSUs will vest on March 6, 2024, and the remainder of the RSUs will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,538 | $19.95 | $30,683.10 |
DisclosureSEC source: 0001209191-23-002803 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,483 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F2 · balance_after: Includes one share acquired on November 15, 2022 through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 08, 2022 Filed Dec 10, 2022 00:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,543 | $15.79 | $40,153.97 |
DisclosureSEC source: 0001209191-22-060580 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,020 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 21:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,296 | $14.26 | $18,480.96 |
DisclosureSEC source: 0001209191-22-053355 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,563 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 22:53 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,772 | $12.26 | $21,724.72 |
DisclosureSEC source: 0001209191-22-049223 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,859 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 20:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,296 | $12.40 | $16,070.40 |
DisclosureSEC source: 0001209191-22-041664 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,631 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. F2 · balance_after: Includes 1,987 shares acquired on May 13, 2022 through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,772 | $9.50 | $16,834.00 |
DisclosureSEC source: 0001209191-22-035219 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,940 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,311 | $12.73 | $16,689.03 |
DisclosureSEC source: 0001209191-22-023840 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,712 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:43 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 7,081 | $12.69 | $89,857.89 |
DisclosureSEC source: 0001209191-22-017646 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,023 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 01:57 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 298,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001209191-22-010447 · doc4.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,000 Underlying: Common Stock · 298,000 shares Expires 2032-02-13 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option will vest on March 1, 2023, and the remainder of the options will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 01:57 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 179,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010447 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,104 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent of the RSUs will vest on March 6, 2023, and the remainder of the RSUs will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 22:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,536 | $13.93 | $21,396.48 |
DisclosureSEC source: 0001209191-22-002496 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,704 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. F2 · balance_after: Includes one share acquired on November 15, 2021 through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 21:03 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,859 | $10.20 | $18,961.80 |
DisclosureSEC source: 0001209191-21-060056 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,239 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| July 06, 2021 Filed Jul 9, 2021 00:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,859 | $25.06 | $46,586.54 |
DisclosureSEC source: 0001209191-21-046078 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,098 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. F2 · balance_after: Includes 684 shares acquired on May 14, 2021 through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 00:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 164,000 | $0.00 Strike: $53.01 | $0.00 |
DisclosureSEC source: 0001209191-21-015005 · doc4.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,000 Underlying: Common Stock · 164,000 shares Expires 2031-02-24 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on March 1, 2022, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 00:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 82,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015005 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,273 F1 · shares: Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on March 6, 2022, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 5,411 | $38.31 | $207,295.41 |
DisclosureSEC source: 0001209191-21-002837 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,273 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. F2 · balance_after: Includes 684 shares acquired on November 13, 2020 through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 10:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | PurchaseCommon Stock | 19,800 | $35.28 | $698,599.44 |
DisclosureSEC source: 0001209191-20-036174 · doc4.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 27,800 F2 · price: The shares were purchased in the open market at prices ranging from $35.22 to $35.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 10:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | PurchaseCommon Stock | 8,000 | $36.29 | $290,282.40 |
DisclosureSEC source: 0001209191-20-036174 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 8,000 F1 · price: The shares were purchased in the open market at prices ranging from $35.75 to $36.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 02:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001209191-20-002645 · doc4.xml · derivative · entry 2 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-01-06 F2 · derivative.exercise_date: Twenty-Five percent of the shares subject to the option vest on January 6, 2021 and the remainder vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 02:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002645 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · kind: Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on January 6, 2021, and the remainder vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 20:37 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 25,000 | $121.00 | $3,025,000.00 |
DisclosureSEC source: 0000059478-19-000103 · wf-form4_155069505836534.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,962 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2018. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:02 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 20,397 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000051 · wf-form4_154949776150306.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,397 Underlying: Common Stock · 20,397 shares Expires 2020-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:02 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 26,681 | $120.17 | $3,206,255.77 |
DisclosureSEC source: 0000059478-19-000051 · wf-form4_154949776150306.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,961 Read SEC document |
| February 04, 2019 Filed Feb 20, 2019 20:43 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 26,682 | $120.17 | $3,206,375.94 |
DisclosureSEC source: 0000059478-19-000107 · wf-form4a_155069540134470.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,962 F1 · shares: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:49 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 12,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000034 · wf-form4_154941055968100.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,222 shares Expires 2019-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:49 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 5,476 | $119.86 | $656,353.36 |
DisclosureSEC source: 0000059478-19-000034 · wf-form4_154941055968100.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,280 Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:49 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 12,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000034 · wf-form4_154941055968100.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 20:22 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 25,000 | $85.00 | $2,125,000.00 |
DisclosureSEC source: 0000059478-18-000163 · wf-form4_152788452675858.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,534 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 8, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.00 to $85.03. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000138 · wf-form4_152537915780405.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 8,934 | $81.07 | $724,279.38 |
DisclosureSEC source: 0000059478-18-000138 · wf-form4_152537915780405.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,534 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000138 · wf-form4_152537915780405.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:12 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000060 · wf-form4_151787233130801.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:12 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 9,512 | $81.45 | $774,752.40 |
DisclosureSEC source: 0000059478-18-000060 · wf-form4_151787233130801.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,468 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:12 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000060 · wf-form4_151787233130801.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 22:57 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 12,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000034 · wf-form4_151743944753235.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,222 Underlying: Common Stock · 12,222 shares Expires 2019-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 22:57 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 12,437 | $87.60 | $1,089,481.20 |
DisclosureSEC source: 0000059478-18-000034 · wf-form4_151743944753235.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,654 Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 20:05 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 34,615 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000251 · wf-form4_151319550696770.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,615 Underlying: Common Stock · 34,615 shares Expires 2021-12-11 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| May 04, 2017 Filed May 8, 2017 19:44 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 25,000 | $82.76 | $2,069,000.00 |
DisclosureSEC source: 0000059478-17-000144 · wf-form4_149427264277920.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,217 F1 · price: This transaction was executed in multiple trades at prices ranging from $82.67 to $82.86. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.